RxSight (RXST) Fundamental Analysis: Revenue, Earnings & Valuation

0.40 / 10

Underperform

Fundamental analysis rates RxSight at 0.4/10, classifying it as Underperform. Profit‑to‑market is modestly positive, but cash‑to‑market, ROA (‑12.36%), and operating cash flow ratios are weak. Asset‑to‑market and revenue‑to‑market are below peers, indicating fragile financial health.

Analysis Checks(6/10)

Revenue-MV

Value-0.75

Score2/3

Weight-42.58%

1M Return1.21%

ROA (%)

Value-12.36

Score2/3

Weight-24.72%

1M Return0.64%

Net cash flow from operating activities / Operating revenue (%)

Value-11.53

Score1/3

Weight44.08%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-126.69%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-12.36

Score2/3

Weight-24.72%

1M Return0.64%

EBIT / Total operating revenue (%)

Value-28.90

Score2/3

Weight-3.79%

1M Return0.10%

Asset-MV

Value-0.55

Score0/3

Weight110.21%

1M Return-3.44%

Net profit / Total operating revenue (%)

Value-28.96

Score1/3

Weight28.47%

1M Return-0.84%

Cash-MV

Value0.02

Score1/3

Weight120.09%

1M Return-4.16%

Net profit / Total profit (%)

Value100.17

Score2/3

Weight19.63%

1M Return-0.54%

Is RXST undervalued or overvalued?

RXST scores 0.40/10 on fundamentals and holds a Premium valuation at present. Backed by its -13.99% ROE, -28.96% net margin, -6.53 P/E ratio, 0.92 P/B ratio, and -33.80% earnings growth, these metrics solidify its Underperform investment rating.